Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMounjaro stops food noise by activating two gut-hormone receptors simultaneously — GIP and GLP-1 — which signals to the brain that the body is fed, reducing the constant background chatter about food that many people experience. This dual-receptor action is unlike any other licensed weight-loss medicine in the UK. Because tirzepatide is a prescription-only medicine, a prescriber assesses whether it is clinically suitable before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Every time tirzepatide is injected, it binds to both the GIP (glucose-dependent insulinotropic polypeptide) receptor and the GLP-1 (glucagon-like peptide-1) receptor. Those two gut hormones exist naturally in the body and are released after eating. They act on the brain's hypothalamus (the area that regulates hunger and satiety) to confirm that a meal has arrived.
The problem for many people with obesity is that this natural signalling system is less sensitive over time. Tirzepatide essentially turns the volume back up on both channels at once. The NHS explains on its tirzepatide medicines page that the medicine works by mimicking these hormones to reduce appetite and slow digestion. Engaging both pathways simultaneously is what sets tirzepatide apart from GLP-1-only medicines like semaglutide, which act on a single receptor. Many people find this dual activation is what tips the balance from persistent hunger to something that finally feels manageable.
For a broader picture of how tirzepatide compares with other weight-loss options, the tirzepatide and food noise overview covers the evidence in detail.
Once tirzepatide activates those receptors, the stomach empties more slowly. Food stays in the digestive system longer, which stretches the physical fullness signal from a short window after a meal into several hours. That matters for food noise specifically because a lot of the mental preoccupation with eating is driven not by genuine hunger but by the body reverting to a low-satiety state quickly after meals.
A quick habit worth trying: when a craving hits, pause and rate your physical hunger from one to ten before acting on it. Many people on tirzepatide find that number is lower than expected. The thought is there; the physical need often is not. That gap is the medicine working.
Slowing gastric emptying also smooths out the blood-sugar fluctuations that can trigger reactive hunger. The result is a steadier internal environment where the brain has less reason to send urgent food-seeking signals. Those on treatment often describe it as the difference between a smoke alarm and background music, the alarm stops sounding.
Thinking about what to eat once the noise reduces? The guide to eating on Mounjaro covers protein, fibre and practical meal strategies.
Most people notice a shift in how often food occupies their thoughts within the first two to four weeks of starting tirzepatide, though it is not uniform. Treatment begins at 2.5mg (a tolerability dose designed to let the body adjust) and the therapeutic effect on appetite tends to build as the dose is titrated upward over successive four-week periods by the prescriber.
NICE's appraisal of tirzepatide (TA1026) reviewed data from the SURMOUNT clinical programme, involving thousands of adults, showing average body-weight reductions of around 20% at the highest dose over 72 weeks. That level of weight loss reflects a sustained reduction in caloric intake, which in turn reflects quieter appetite signals over a long period, not a brief honeymoon effect.
Individual variation is real. Stress, sleep, alcohol and ultra-processed foods can all partially override the medicine's appetite-regulating effect. Dose increases, reviewed every four weeks with a prescriber, help where the initial dose has not achieved sufficient quieting. For those wondering whether Mounjaro stops eating urges more broadly, the answer depends on dose, lifestyle factors and individual biology, which is exactly what a clinical review explores.
If food noise has crept back in after a period of quiet, it is worth reading about why food noise can return on Mounjaro and what changes typically help.
As appetite and gastric emptying change, some people experience nausea, loose stools, constipation or indigestion, most commonly in the first one to two weeks after a new dose or a dose increase. These effects usually settle as the body adapts. They are covered in full on the NHS tirzepatide page alongside other things to watch for.
One less-discussed side effect is changes to breath. Reduced food intake shifts the body towards fat metabolism, which can alter breath chemistry. If that is a concern, managing breath changes on Mounjaro offers practical steps. None of these effects change how the medicine acts on food noise; they reflect the body adjusting to a new metabolic state.
Because tirzepatide is a prescription-only medicine, the prescriber reviews the full clinical picture before starting treatment and before any dose change. That includes any history that might affect how the medicine works or which side effects to watch for most closely. For a fuller introduction to the medicine itself, the Mounjaro overview is the place to start. If cost is a consideration, the Mounjaro pricing guide explains what a legitimate private prescription includes. When you are ready to find out whether tirzepatide is clinically suitable for you, speak to our prescribers, the consultation is free and reviewed the same day by a GPhC-registered prescriber, not an automated system.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.